Status:
UNKNOWN
Ocular Allergy Treatment Practical Impact Trial
Lead Sponsor:
Starx Research Center, LLC
Conditions:
Allergic Conjunctivitis
Rhinoconjunctivitis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To study the impact of alcaftadine in patients treated with other opthalmic ocular agents (or specific topical opthalmic treatment) in an allergy subspecialist outpatient setting.
Detailed Description
To assess the impact of ocular allergy treatment on patients using an ophthalmic agent (or no treatment) versus alcaftadine(Lastacaft™)
Eligibility Criteria
Inclusion
- patients age 18 and older with a history of seasonal or perennial forms of allergic conjunctivitis and skin test positive reactivity to seasonal aeroallergens
- Total Ocular Symptom Score (TOSS) on the day of enrollment of 4 or more.
- have allergic ocular symptoms for the past week for which they are either treating with ophthalmic agents or have had no treatment.
- Are willing/able to follow instructions from the study investigator and his/her study staff.
- Have signed infromed consent approved by Institutional Review Board or Independent Ethics Committee.
- \-
Exclusion
- Active ocular infection;
- History of retinal detachment, diabetic neuropathy, or any progressive retinal disease;
- Ocular surgical intervention within three (3) months prior to visit 1 or scheduled during the study.
- History of unstable, or uncontrolled disease of any nature.
- Pregnancy or lactation;
- Have a known hypersensitivity tp LASTACAFT™ (alcaftadine) -
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2013
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT01808768
Start Date
April 1 2013
End Date
November 1 2013
Last Update
May 30 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
STARx Research Center
Edison, New Jersey, United States, 08820
2
STARx
Springfield, New Jersey, United States, 07081